PRODUCT INFORMATION

Bimeda®

Global Excellence in Animal Health

Buparvex Inj. (Buparvaquone)

Buparvex™ (BUPARVAQUONE)

Presentation: Buparvex is a clear red solution for intramuscular injection. Each 1ml contains 50mg buparvaquone.

Indications: Buparvex is indicated for the treatment of all forms of theileriosis of cattle.

North Africa, Middle East, Southern Europe, India and Asia - *Mediterranean or Tropical* theileriosis caused by Theileria annulata.

Eastern Africa - East Coast Fever (ECF) caused by Theileria parva. T. parva also causes Corridor Disease of cattle in areas populated by the African buffalo (Syncerus caffer). Buparvex is used to treat clinical cases of theileriosis. It may also be used during the incubation period to prevent clinical disease in animals that are known to be infected but not yet showing clinical signs. Buparvaquone kills theilerial schizonts (in lymphoid cells) and piroplasms (in red blood cells) and it suppresses pre-schizont stages during the incubation period of the disease. It kills the parasites through its action on their mitochondrial electron transport (respiratory) system. Usually it does not completely eliminate the infection so cured animals continue to carry a sub-clinical infection.

Dosage and Administration: 1ml of Buparvex per 20Kg bodyweight (2.5mg buparvaquone per Kg) injected intramuscularly is usually sufficient to cure moderate cases of theileriosis. More advanced cases may require one or more additional, similar, injections. These should be given with an interval of two or three days between injections, as clinically indicated. Injections should be given into the neck muscles because the drug mobilises best from this site.

If Buparvex is used to suppress theileriosis during its incubation period, a single dose of 1ml per 20Kg bodyweight, injected into the neck muscles, is usually sufficient to prevent the development of clinical signs.

Warnings and Precautions: Buparvex must be administered only by the intramuscular route. It must not be injected intravenously. Buparvex is poorly mobilised after subcutaneous injection and its curative effect is greatly reduced.

Adverse effects: Localised swelling may occur at injection sites but it resolves in a few days. Buparvaquone is very safe so over-dosage is unlikely to cause significant adverse effects.

Withholding Periods: Milk for human consumption should not be taken from animals treated with Buparvex until at least 48 hours after treatment. Milk from animals treated with Buparvex is safe for consumption by calves. Animals should not be slaughtered for human consumption until at least 42 days after treatment with Buparvex.

50ml glass vial



FOR ANIMAL TREATMENT ONLY, KEEP OUT OF THE REACH OF CHILDREN, STORE BETWEEN 2° and 25° C
PROTECT FROM LIGHT

BIMEDA LTD.
Funzi Road, Industrial Area. P.O. Box 30620-00100,
Nairobi, Kenya
Tel: +254 20 6537622-6 Fax: +254 20 6537628

www.bimeda.com